- Home
- PSNL vs NTRB Comparison
PSNL vs NTRB Comparison
Compare PSNL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- NTRB
- Stock Information
- Founded
- PSNL 2011
- NTRB 2016
- Country
- PSNL United States
- NTRB United States
- Employees
- PSNL N/A
- NTRB N/A
- Industry
- PSNL Medical Specialities
- NTRB Industrial Specialties
- Sector
- PSNL Health Care
- NTRB Health Care
- Exchange
- PSNL Nasdaq
- NTRB Nasdaq
- Market Cap
- PSNL 321.1M
- NTRB 77.9M
- IPO Year
- PSNL 2019
- NTRB N/A
- Fundamental
- Price
- PSNL $5.19
- NTRB $6.17
- Analyst Decision
- PSNL Strong Buy
- NTRB
- Analyst Count
- PSNL 4
- NTRB 0
- Target Price
- PSNL $6.81
- NTRB N/A
- AVG Volume (30 Days)
- PSNL 439.4K
- NTRB 28.2K
- Earning Date
- PSNL 11-06-2024
- NTRB 12-11-2024
- Dividend Yield
- PSNL N/A
- NTRB N/A
- EPS Growth
- PSNL N/A
- NTRB N/A
- EPS
- PSNL N/A
- NTRB N/A
- Revenue
- PSNL $80,027,000.00
- NTRB $1,803,816.00
- Revenue This Year
- PSNL $10.85
- NTRB N/A
- Revenue Next Year
- PSNL $8.77
- NTRB N/A
- P/E Ratio
- PSNL N/A
- NTRB N/A
- Revenue Growth
- PSNL 19.20
- NTRB N/A
- 52 Week Low
- PSNL $0.89
- NTRB $1.93
- 52 Week High
- PSNL $7.20
- NTRB $9.60
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- NTRB 50.57
- Support Level
- PSNL $4.54
- NTRB $5.24
- Resistance Level
- PSNL $5.35
- NTRB $6.40
- Average True Range (ATR)
- PSNL 0.30
- NTRB 0.71
- MACD
- PSNL 0.05
- NTRB -0.12
- Stochastic Oscillator
- PSNL 84.71
- NTRB 33.23
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.